Combined intravitreal bevacizumab injection and zone i sparing laser photocoagulation in patients with zone i retinopathy of prematurity

Retina

Volumn 34, Issue 1, 2014, Pages 77-82

  Kim, Jaer Yung ^a   Kim, Sang Jin ^a   Chang, Yun Sil ^a   Park, Won Soon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bevacizumab; Laser photocoagulation; Retinopathy of prematurity

Indexed keywords

BEVACIZUMAB;

ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFANT; LASER COAGULATION; RETINA MACULA LUTEA; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SURGICAL ANATOMY; TREATMENT OUTCOME; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; GESTATIONAL AGE; HUMANS; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INTRAVITREAL INJECTIONS; LASER COAGULATION; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84891872476     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318296e26d     Document Type: Article

References (28)

1. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS 1999;3:26-32.
2. Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina 2010;30:37-40.
3. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity clinical characteristics and treatment outcomes. Retina 2006;26:S11-S15.
4. O'Keefe M, Lanigan B, Long VW. Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 2003;81:614-616.
5. Onofrey CB, Feuer WJ, Flynn JT. The outcome of retinopathy of prematurity. Ophthalmology 2001;108:27-35.
6. Hatsukawa Y, Ueki N, Yamagishi T, Kitajima H. The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes. Jpn J Ophthalmol 2005;49:391-396.
7. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364:603-615.
8. Hård AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review. Acta Paediatr 2011;100:1523-1527.
9. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 2012;16: 2-4.
10. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-333.
11. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med 2012;367: 2515-2526.
12. Spandau U, Tomic Z, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 2013;91:170-175.
13. Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000-1006.
14. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730.
15. Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010;248:1257-1262.
16. Nazari H, Modarres M, Parvaresh MM, et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 2010;248:1713-1718.
17. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-576.
18. Coats DK, Miller AM, Hussein MA, et al. Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment. Am J Ophthalmol 2005;140:214-222.
19. Shapiro MJ, Gieser JP, Warren KA, et al. Zone I retinopathy of prematurity. In: Shapiro MJ, Biglan AW, Miller M, eds. Retinopathy of Prematurity. Proceedings of The International Conference on Retinopathy of Prematurity. Chicago, IL: Kugler Publications; 1993:149-155.
20. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063.
21. Wu WC, Yeh PT, Chen SN, et al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118:176-183.
22. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010;30:S24-S31.
23. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28: 831-838.
24. Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6-10.
25. Schachat AP, Chambers WA, Liesegang TJ, Albert DA. Safe and effective. Ophthalmology 2003;110:2073-2074.
26. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-S18.
27. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113.
28. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319.